Menu
  • Join
  • Login
  • Contact
 

Search abstracts


INNOVATION OF GENERIC DRUGS IN THE TAIWAN PHARMACEUTICAL INDUSTRY– HEPARIN DEVELOPMENT

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: WU, Yi Ting (Bionovax Corp, Quality Control Department, China Taiwan)
  • Co-author(s): Yi-Ting Wu: Quality Control Dept., Bionovax Corp., Taoyuan, China Taiwan;, Taipei Pharmacists Association, Taipei, China Taiwan
    Ming-Hong Chuang: Research and Development Dept., Bionovax Corp., Taoyuan, China Taiwan
  • Abstract:

    Background

    Heparin in Taiwan was simply imported from other countries from 1943 to 1993. Since 1993, we began preparing generic Heparin. From that time on, we imported Heparin Active Pharmaceutical Ingredient (Hp API) from countries, such as the U.S., China, and India, to manufacture Heparin Injection or topical heparin preparations. Some scholars..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses